CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02155634
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:57.696333+00:00
Published At: 2018-04-10T00:00:00+00:00
Record Updated At: 2018-04-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Multiple Myeloma", "Neoplasms", "Plasma Cells", "Paraproteinemias", "Blood Protein Disorders", "Hematologic Diseases", "Therapeutic Uses"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-04-10"
protocolSection.identificationModule.nctId: "NCT02155634"
protocolSection.identificationModule.officialTitle: "Phase 3b, Randomized Trial of Continuous Revlimid\u00ae (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst\u00ae or Thalomid\u00ae in Newly Diagnosed Multiple Myeloma"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.